Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    249 result(s) found for: Cancer vaccine. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000164-24 Sponsor Protocol Number: 109836 Start Date*: 2007-05-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007783-14 Sponsor Protocol Number: 111507 Start Date*: 2008-04-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) co-administrated with GlaxoSmit...
    Medical condition: For the prevention of high grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: NL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003573-58 Sponsor Protocol Number: 2025 Start Date*: 2021-08-09
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancEr: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000369-44 Sponsor Protocol Number: 111375 Start Date*: 2009-03-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011357-41 Sponsor Protocol Number: 112772 Start Date*: 2009-07-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the fir...
    Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004889-35 Sponsor Protocol Number: UCDCRC/21/10 Start Date*: 2021-12-08
    Sponsor Name:University College Dublin
    Full Title: An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a booster mRNA vaccination dose against SARS-Co...
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 19 (COVID-19/SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NO (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000300-38 Sponsor Protocol Number: 001610 Start Date*: 2021-02-05
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000120-19 Sponsor Protocol Number: HN1901 Start Date*: 2020-05-05
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Activity and safety of peptide-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.
    Medical condition: Head and neck cancer elective for surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000757-22 Sponsor Protocol Number: 114700 Start Date*: 2011-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscu...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020233-56 Sponsor Protocol Number: DC-006 Start Date*: 2011-03-24
    Sponsor Name:Oslo University Hospital
    Full Title: PHASE I/II TRIAL OF VACCINE THERAPY IN RELAPSED AND PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS USING AUTOLOGOUS DENDRITIC CELLS LOADED WITH AMPLIFIED OVARIAN CANCER STEM CELL mRNA, hTE...
    Medical condition: Relapsed and platinum resistant epithelial ovarian carcinoma patients that have received one line of non-platinum chemotherapy in resistance disease setting.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003652-37 Sponsor Protocol Number: V212-001-00 Start Date*: 2007-03-02
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZ...
    Medical condition: Herpes zoster (HZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000725-27 Sponsor Protocol Number: 2020-000725-27 Start Date*: 2020-05-28
    Sponsor Name:Center for Surgical Science, Department of Surgery, Zealand University Hospital
    Full Title: Intratumoral Influenza Vaccine for Early Colorectal Cancer
    Medical condition: Patients with colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010032 Colorectal cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010033 Colorectal cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002083-13 Sponsor Protocol Number: HPVfollowup Start Date*: 2016-07-21
    Sponsor Name:Public Health England
    Full Title: An observational follow up study of a randomised parallel group phase IV study to evaluate the duration of the immune response to vaccine and non-vaccine HPV types in UK adolescent females who rece...
    Medical condition: No specific medical condition - immune reponses to HPV vaccination.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000934-38 Sponsor Protocol Number: CP-BR-1-2007 Start Date*: 2007-10-30
    Sponsor Name:Generex Biotechnology Corporation
    Full Title: Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vacci...
    Medical condition: Disease-free, conventionally treated node-positive and high-risk node-negative breast cancer patients who are at significant risk for recurrence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020227-48 Sponsor Protocol Number: 113618 Start Date*: 2011-01-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18....
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001325-14 Sponsor Protocol Number: 580299/008 Start Date*: 2004-08-12
    Sponsor Name:GlaxoSmithKline SA
    Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit...
    Medical condition: cervical cancer => study is conducted in healthy female
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002777-32 Sponsor Protocol Number: 110659 Start Date*: 2007-10-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’...
    Medical condition: For active immunization of females for the prevention of cervical cancer by protecting against persistent infections, cytological abnormalities including atypical squamous cells of undetermined sig...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000518-37 Sponsor Protocol Number: 580299/013 Start Date*: 2004-08-27
    Sponsor Name:GlaxoSmithKline AS
    Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly according t...
    Medical condition: cervical cancer: the study is conducted in healthy female adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: NO (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005943-24 Sponsor Protocol Number: 580299/011 Start Date*: 2006-03-29
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according t...
    Medical condition: In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 11:05:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA